JP2016519107A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016519107A5 JP2016519107A5 JP2016507634A JP2016507634A JP2016519107A5 JP 2016519107 A5 JP2016519107 A5 JP 2016519107A5 JP 2016507634 A JP2016507634 A JP 2016507634A JP 2016507634 A JP2016507634 A JP 2016507634A JP 2016519107 A5 JP2016519107 A5 JP 2016519107A5
- Authority
- JP
- Japan
- Prior art keywords
- hypoxia
- predetermined value
- cancer
- degree
- administering
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 206010021143 Hypoxia Diseases 0.000 claims 5
- 206010028980 Neoplasm Diseases 0.000 claims 5
- 201000011510 cancer Diseases 0.000 claims 5
- 230000007954 hypoxia Effects 0.000 claims 5
- 238000012879 PET imaging Methods 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361810643P | 2013-04-10 | 2013-04-10 | |
| US61/810,643 | 2013-04-10 | ||
| PCT/US2014/033491 WO2014169035A1 (en) | 2013-04-10 | 2014-04-09 | Predictive and response biomarker for th-302 anti-cancer therapy |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016519107A JP2016519107A (ja) | 2016-06-30 |
| JP2016519107A5 true JP2016519107A5 (enExample) | 2017-06-01 |
Family
ID=51689977
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016507634A Pending JP2016519107A (ja) | 2013-04-10 | 2014-04-09 | Ｔｈ−３０２抗癌療法のための予測および応答のバイオマーカー |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20160296538A1 (enExample) |
| EP (1) | EP2983591A4 (enExample) |
| JP (1) | JP2016519107A (enExample) |
| WO (1) | WO2014169035A1 (enExample) |
Families Citing this family (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2015069489A1 (en) | 2013-11-06 | 2015-05-14 | Merck Patent Gmbh | Predictive biomarker for hypoxia-activated prodrug therapy |
| CN114224894B (zh) | 2014-12-03 | 2025-01-07 | 奥克兰联合服务有限公司 | 用于治疗癌症的激酶抑制剂前药 |
| US11504075B2 (en) * | 2017-12-20 | 2022-11-22 | University Health Network | System, methods, and devices for calculating hypoxic fraction and equilibration rate of small molecular weight tracers using dynamic imaging |
| US20240366640A1 (en) | 2021-08-27 | 2024-11-07 | Ascentawits Pharmaceuticals, Ltd. | Lyophilized formulation solution and lyophilized formulation, and method and use thereof |
| KR20240051965A (ko) | 2021-08-27 | 2024-04-22 | 아센타위츠 파마슈티컬즈 리미티드 | Th-302를 이용한 parp 억제제에 내성이 있는 환자의 치료 |
| EP4494643A4 (en) | 2022-03-15 | 2025-09-10 | Ascentawits Pharmaceuticals Ltd | METHOD OF TREATING A PATIENT WITH BRCA MUTATION CANCER |
| WO2023198188A1 (zh) | 2022-04-15 | 2023-10-19 | 深圳艾欣达伟医药科技有限公司 | 使用th-302单药或联用parp抑制剂治疗癌症的方法 |
| WO2023226959A1 (zh) | 2022-05-23 | 2023-11-30 | 深圳艾欣达伟医药科技有限公司 | 烷化剂前药与细胞周期抑制剂联用治疗癌症的方法 |
| EP4591866A1 (en) | 2022-09-22 | 2025-07-30 | Ascentawits Pharmaceuticals, Ltd. | Use of hypoxia-activated compound in preparation of medicament for treating cancer patient |
| KR20250160163A (ko) | 2023-02-27 | 2025-11-11 | 아센타위츠 파마슈티컬즈 리미티드 | 용액, 동결건조 제형, 동결건조 제형 단위 패키지, 주사제, 및 주사제 제조 방법 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2002252456A1 (en) * | 2001-03-23 | 2002-10-08 | Aphton Corporation | Combination treatment of pancreatic cancer |
| US20070117784A1 (en) * | 2005-03-04 | 2007-05-24 | Novacea, Inc. | Treatment of hyperproliferative diseases with anthraquinones |
| ES2884674T3 (es) * | 2008-10-21 | 2021-12-10 | Immunogenesis Inc | Tratamiento del cáncer con el profármaco activado por hipoxia TH-302 en combinación con docetaxel o pemetrexed |
| MX2012014416A (es) * | 2010-06-28 | 2013-02-27 | Threshold Pharmaceuticals Inc | Tratamiento de cancer de sangre. |
| ES2877629T3 (es) * | 2010-07-12 | 2021-11-17 | Immunogenesis Inc | Administración de profármacos activados por hipoxia y agentes antiangiogénicos para el tratamiento del cáncer |
| US10357577B2 (en) * | 2010-07-16 | 2019-07-23 | Auckland Uniservices Limited | Bacterial nitroreductase enzymes and methods relating thereto |
-
2014
- 2014-04-09 WO PCT/US2014/033491 patent/WO2014169035A1/en not_active Ceased
- 2014-04-09 JP JP2016507634A patent/JP2016519107A/ja active Pending
- 2014-04-09 EP EP14783066.5A patent/EP2983591A4/en not_active Withdrawn
- 2014-04-09 US US14/783,776 patent/US20160296538A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2016519107A5 (enExample) | ||
| ZA202107358B (en) | Method for treating alzheimer's disease | |
| MX2023000796A (es) | Composicion farmaceutica, metodos para tratamiento y sus usos. | |
| IN2015DN00450A (enExample) | ||
| MX2017014338A (es) | Seleccion dirigida de pacientes para el tratamiento con derivados de cortistatina. | |
| BR112022002609A2 (pt) | Métodos de tratamento de tumores estromais gastrointestinais | |
| CY1123501T1 (el) | Χρηση ρεσλιζουμαμπης για τη θεραπευτικη αντιμετωπιση μετριου εως σοβαρου ηωσινοφιλικου ασθματος | |
| EA201591290A2 (ru) | Креноланиб для лечения пролиферативных расстройств, связанных с мутацией flt3 | |
| PH12017500392A1 (en) | Medical treatments based on anamorelin | |
| CN111989095A (zh) | 预防或治疗肿瘤疗法副作用的方法 | |
| EA201691656A2 (ru) | Терапевтические способы с применением норибогаина и родственных соединений | |
| NZ754328A (en) | Marker for acid sphingomyelinase disorders and uses thereof | |
| JP2013536236A5 (enExample) | ||
| IL264407A (en) | Novel application of gzd824 and pharmaceutically acceptable salts thereof in treating diseases | |
| PH12016502233A1 (en) | (s)-pirlindole or its pharmaceutically acceptable salts for use in medicine | |
| JP2014201591A5 (enExample) | ||
| HUE066609T2 (hu) | Adagolási forma betegség kezelésében vagy megelõzésében történõ alkalmazásra | |
| JP2019513151A5 (enExample) | ||
| MX2021007324A (es) | Terapia oral con acido 6,8-bis-benciltio-octanoico. | |
| Estenkova et al. | About the SPA and resort-based treatment of the patients with oncological diseases | |
| Yamada | Febrile neutropenia and peripheral nerve injuries: 3 case reports | |
| Yu et al. | CLINICAL INVESTIGATION OF THERAPEUTIC EFFECT OF HUO ZHEN AND HERBAL FUMIGANT IN TREATING ARTHRALGIA SYNDROME | |
| Davies | Acquired resistance in non-small cell lung cancer: case report | |
| Stepanov et al. | Experience of Vasonat usage in treatment of patients with chronic toxic hepatitis | |
| Kilincalp | Azathioprine/corticosteroid |